Genomic linkage between alzheimer's disease and type 2 diabetes

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 2, 2014, Pages 203-212

  Nedjadi, Taoufik ^a   Haque, Absarul ^a   Alam, Qamre ^a   Gan, Siew H ^b   Chaudhary, Adeel G ^a   Abuzenadah, Adel M ^a   Damanhouri, Ghazi A ^a   Kamal, Mohammad A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Alzheimer's disease; Genes; Insulin; Insulin resistance; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN E4; CHOLESTEROL; INSULIN; SOMATOMEDIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIET; DISEASE COURSE; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; INCIDENCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; ANIMAL; BRAIN; DIABETES MELLITUS, TYPE 2; GENETICS; GENOMICS; HUMAN; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; GENOMICS; HUMANS; INSULIN;

EID: 84904507361     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660140     Document Type: Review

References (153)

1. Andrieu S, Aboderin I, Baeyens JP, et al. IAGG workshop: health promotion program on prevention of late onset dementia. J Nutr Health Aging 2011; 15(7): 562-75.
2. Stefanacci RG. The costs of Alzheimer's disease and the value of effective therapies. Am J Manag Care 2011; 17(SUPPL.13): 356-62.
3. Fiţa IG, Enciu AM, Stǎnoiu BP. New insights on Alzheimer's disease diagnostic. RomJMorphol Embryol 2011; 52(SUPPL 3): 975-9.
4. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann NY Acad Sci 1999; 893: 154-75.
5. Götz J, Ittner LM, Lim YA. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 2009; 66(8): 1321-5.
6. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetesevidence reviewed. J Diab Sci Technol 2008; 2(6): 1101-13.
7. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 2004; 26(8): 1044-80.
8. Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia 2006; 49(12): 2859-65.
9. Driver JA, Smith A, Buring JE, et al. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008; 31(10): 2003-5.
10. Hu G, Jousilahtip P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabet Care 2007; 30(4): 842-7.
11. Yaffe K, Blackwell T, Kanaya AM, et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63(4): 658-63.
12. Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology 2011; 77(12): 1126-34.
13. Jiménez-Palomares M, Ramos-Rodríguez JJ, López-Acosta JF, et al. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab 2012; 302(11): E1373-80.
14. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 2010; 107(15): 7036-41.
15. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009; 42(8): 475-81.
16. Grand JH, Caspar S, Macdonald SW. Clinical features and multidisciplinary approaches to dementia care. J Multidisciplin Healthcare 2011;4: 125-47.
17. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56(3): 303-8.
18. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 2006; 367(9518): 1262-70.
19. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119(4): 252-65.
20. Rountree SD, Waring SC, Chan WC, et al. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord 2007; 24(6): 476-82.
21. Brooks LG, Loewenstein DA. Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Ther 2010; 2(5): 28.
22. Belleville S, Sylvain-Roy S, de Boysson C, Ménard MC. Characterizing the memory changes in persons with mild cognitive impairment. Prog Brain Res 2008; 169: 365-75.
23. Qiu C, Kivipelto M, von SE. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11(2): 111-28.
24. Simon SS, Yokomizo JE, Bottino CM. Cognitive intervention in amnestic Mild Cognitive Impairment: a systematic review. Neurosci Biobehav Rev 2012; 36(4): 1163-78.
25. Wimo A, Winblad B. Societal burden and economics of vascular dementia: preliminary results from a Swedish-population-based study. Int Psychogeriatr 2003; 15(1): 251-6.
26. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002; 59(11): 1737-46.
27. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262(18): 2551-6.
28. Povova J, Ambroz P, Bar M, et al. Vladimir Janouta. Epidemiological of and risk factors for Alzheimer's disease: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156(2): 108-14.
29. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368(9533): 387-403.
30. Profenno LA, Faraone SV. Diabetes and overweight associate with non-APOE4 genotype in an Alzheimer's disease population. Am J Med Genet B Neuropsychiatr Genet 2008; 147B(6): 822-9.
31. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71(3): 365-76.
32. Martins IJ, Berger T, Sharman MJ, et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem 2009; 111(6): 1275-308.
33. Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2006; 2(3): 159-66.
34. Carlsson CM. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimer's Dis 2010; 20(3): 711-22.
35. Tchantchou F, Graves M, Ortiz D, et al. S-adenosyl methionine: A connection between nutritional and genetic risk factors for neurodegeneration in Alzheimer's disease. J Nutr Health Aging 2006; 10(6): 541-4.
36. Chan A, Shea TB. Folate deprivation increases presenilin expression, gamma-secretase activity, and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S-adenosyl methionine. J Neurochem 2007; 102(3): 753-760.
37. Hughes TM, Kuller LH, Lopez OL, et al. Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. J Alzheimer's Dis 2012; 30(1): 53-61.
38. Wysocki M, Luo X, Schmeidler J, et al. Hypertension is associated with cognitive decline in elderly people at high risk for dementia. Am J Geriatr Psychiatr 2012; 20(2): 179-87.
39. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10(9): 819-28.
40. Mehta M, Adem A, Kahlon MS, Sabbagh MN. The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited. Front Biosci (Elite Ed) 2012; 4: 169-80.
41. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of populationbased cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54(11 SUPPL 5): S10-5.
42. Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke 2008; 39(1): 36-41.
43. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112-7.
44. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of populationbased cohorts. Neurologic Diseases in the Elderly Research Group. Neurol 2000; 54(11 SUPPL 5): S4-9.
45. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007; 29(1-2): 125-32.
46. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008; 7(9): 812-26.
47. Al Rajeh S, Bademosi O, Ismail H, et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology 1993; 12(3): 164-78.
48. Farrag A, Farwiz HM, Khedr EH, Mahfouz RM, Omran SM. Prevalence of Alzheimer's disease and other dementing disorders: Assiut-Upper Egypt study. Dement Geriatr Cogn Disord 1998; 9(6): 323-8.
49. El Tallawy HN, Farghly WM, Shehata GA, et al. Prevalence of dementia in Al Kharga District, New Valley Governorate, Egypt. Neuroepidemiology 2012; 38(3): 130-7.
50. Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 2009; 9(5): 617-30.
51. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
52. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999; 52(5): 971-5.
53. Razay G, Wilcock GK. Hyperinsulinaemia and Alzheimer's disease. Age Ageing 1994; 23(5): 396-9.
54. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63(7): 1187-92.
55. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010; 67(6): 505-12.
56. Sima AA, Li ZG. Diabetes and Alzheimer's disease is there a connection? Rev Diabetes Stud 2006; 3(4): 161-8.
57. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimer's Dis 2006; 10(1): 89-109.
58. Hölscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 2011; 39(4): 891-7.
59. Sahin M, Karatas M, Ertugrul D, et al. High prevalence of neuropathy in patients with impaired 60-minute oral glucose tolerance test but normal fasting and 120-minute glucose levels. Miner Endocrinol 2008; 33(4): 289-96.
60. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004; 490(1-3): 115-25.
61. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 2011; 15(9): 1807-21.
62. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulinlike growth factor expression and signalling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimer's Dis 2005; 7: 63-80.
63. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimer's Dis 2005; 8: 247-68.
64. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991; 12: 295-312.
65. Mark A, Fishel G, Stennis W, Thomas J, Montine. Hyperinsulinemia Provokes Synchronous Increases in Central Inflammation and -Amyloid in Normal Adults. Arch Neurol 2005; 62: 1539-44.
66. Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr Diab Rep 2004; 4: 237-46.
67. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-92.
68. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurol 1999; 53: 1937-42.
69. Montine TJ, Kaye JA, Montine KS, et al. Cerebrospinal fluid abeta42: tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other, dementias, and in age-matched controls. Arch Pathol Lab Med 2001; 125: 510-2.
70. Cacquevel M, Lebeurrier N, Cheenne S, Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 2004; 5: 529-34.
71. Sheng JG, Bora SH, Xu G, et al. Lipopolysaccharideinducedneuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 2003; 14: 133-45.
72. Gasparini L, Gouras GK, Wang R, et al. Stimulation of betaamyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signalling. J Neurosci 2001; 21: 2561-70.
73. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273: 32730-8.
74. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009; 31: 42(8): 475-81.
75. Han W, Li C. Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci USA 2010; 107: 6557-8.
76. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimer's Dis 2009; 16(4): 741-61.
77. Freude S, Plum L, Schnitker J, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 2005; 54(12): 3343-8.
78. Hoyer S. Brain glucose and energy metabolism during normal aging. Aging 1990; 2(3): 245-58.
79. Bingham EM, Hopkins D, Smith D. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002; 51(12): 3384-90.
80. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006; 209: 2304-11.
81. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 2001; 177(1-2): 125-34.
82. Tun PA, Nathan DM, Perlmuter LC. Cognitive and affective disorders in elderly diabetics. Clin Geriatr Med 1990; 6: 731-46.
83. de Weid D, Bohus B, Wimersma TB, Greidanus. Memory deficit in rats with hereditary diabetes insipidus. Brain Res 1975; 85(1): 152-6.
84. Stranahan AM, Arumugam TV, Cutler RG, et al. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci 2008; 11(3): 309-17.
85. D'Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina, G. The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 1996; 13: 227-55.
86. Chiu S, Chen C, Cline H. Insulin Receptor Signalling Regulates Synapse Number, Dendritic Plasticity, and Circuit Function In Vivo. Neuron 2008; 58(5): 708-19.
87. Havrankova J, Brownstein M, Roth J. Insulin receptors are widely but unevenly distributed in central nervous-system of rat. Clin Res 1978; 26: 491A.
88. Havrankova J, Roth J. Insulin receptors are widely distributed in central nervoussystem of rat. Nature 1978; 272(5656): 827-9.
89. Marks JL, Porte D, Stahl WL, Baskin DG. Localization of insulinreceptor messenger-RNA in rat-brain by insitu hybridization. Endocrinology 1990; 127(6): 3234-46.
90. Zhao WQ, Chen H, Xu H, et al. Brain insulin receptors and spatial memory correlated changes in gene expression, tyrosine phosphorylation, and signalling molecules in the hippocampus of water maze trained rats. J Biol Chem 1999; 274(49): 34893-902.
91. Werther GA, Hogg A, Oldfield BJ, et al. Localization and characterization of insulin-receptors in rat-brain and pituitarygland using invitro autoradiography and computerized densitometry. Endocrinology 1987; 121: 1562-70.
92. Small SA, Gandy S. Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis. Neuron 2006; 52(1): 15-31.
93. Smith MA, Monnier VM, Sayre LM, Perry G. Amyloidosis, advanced glycation end products and Alzheimer disease. Neuro Report 1995; 6: 1595-6.
94. Smith MA, Sayre LM, Monnier VM, Perry G. Radical Ageing in Alzheimer's disease. Trends Neurosci 1995; 18(4): 172-6.
95. Zhao W, Chen H, Xu H, et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signalling molecules in the hippocampus of water maze trained rats. J Biol Chem 1999; 274: 34893-902.
96. Kasuga M, Zick Y, Blith DL, et al. Insulin stimulation of phosphorylation of the beta-subunit of the insulin-receptorformation of both phosphoserine and phosphotyrosine. J Biol Chem 1982; 257: 9891.
97. Kahn CR, Folli F. Molecular determinants of insulin action. Horm Res 1993; 39(Suppl 3): 93-101.
98. Johnson-Farley NN, Patel K, Kim D, Cowen DS. Interaction of FGF-2 with IGF-1 and BDNF in stimulating Akt, ERK, and neuronal survival in hippocampal cultures. Brain Res 2007; 1154: 40-9.
99. Johnston AM, Pirola L, Van Obberghen E. Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling. FEBS Lett 2003; 546: 32-6.
100. Sui L, Wang J, Li BM. Role of the phosphoinositide 3-kinase Aktmammalian target of the rapamycin signalling pathway in longterm potentiation and trace fear conditioning memory in rat medial prefrontal cortex. Learn Mem 2008; 15: 762-76.
101. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
102. Peineau S, Taghibiglou C, Bradley C, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007; 53: 703-17.
103. Hooper C, Markevich V, Plattner F, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 2007; 25: 81-6.
104. Zhu LQ, Wang SH, Liu D, et al. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 2007; 27: 12211-20.
105. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82: 510-29.
106. Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signalling in brain aging and Alzheimer's Disease. Exp Gerontol 2007; 42: 10-21.
107. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabet Care 2001; 24(3): 588-97.
108. Heidenreich KA, Zahniser NR, Berhanu P, Brandenburg D, Olefsky JM. Structural differences between insulin receptors in the brain and peripheral target tissues. J Biol Chem 1983; 258(14): 8527-30.
109. Stolk RP, Pols HA, Lamberts SW, et al. Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study, Am J Epidemiol 1997; 145(1): 24-32.
110. Stolk RP, Breteler MM, Ott A, et al. Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabet Care 1997; 20(5): 792-5.
111. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995; 38: 1096-102.
112. Frolich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105(4-5): 423-38.
113. Frolich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann NY Acad Sci 1999; 893: 290-3.
114. De la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009; 4298): 475-81.
115. Alper J. Biomedicine: new insights into type 2 diabetes. Science 2000; 289: 37-9.
116. Jonsaton AM, Pirola L, Van Obberghen E. Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling. FEBS Lett 2003; 546: 32-36.
117. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000; 103: 211-25.
118. Giovannone B, Scaldaferri ML, Federici M, et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signalling potential. Diabetes Metab Res Rev 2000; 16: 434-41.
119. Sun XJ, Crimmins DL, Myers MJ, Miralpeix M, White MF. Pleiotropic insulin signals are en gaged by multisite phosphorylation of IRS-1. Mol Cell Biol 1993; 13: 7418-28.
120. Paz K, Hemi R, LeRoith D, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997; 272: 29911-98.
121. Lam K, Carpenter CL, Ruderman NB, Friel JC, Kelly KL. The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. J Biol Chem 1994; 269: 20648-52.
122. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275: 661-5.
123. Condorelli F, Salomoni P, Cotteret S, et al. Caspase cleavage enhances the apoptosis-inducing effects of BAD. Mol Cell Biol 2001; 21: 3025-36.
124. Halestrap AP, Doran E, Gillespie JP, O'Toole A. Mitochondria and cell death. Biochem Soc Trans 2000; 28: 170-7.
125. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signalling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimer's Dis 2005; 7: 45-61.
126. Eckman EA, Eckman CB. Abeta-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005; 33: 1101-5.
127. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the betaamyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003; 100: 4162-7.
128. Fewlass DC, Noboa K, Pi-Sunyer FX, et al. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J 2004;18(15): 1870-8.
129. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 423: 435-9.
130. Cole AR, Astell A, Green C, Sutherland C. Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 2007; 31: 1046-63.
131. Ling Y, Morgan K, Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int J Biochem Cell Biol 2003; 35: 1505-35.
132. Mukherjee A, Song E, Kihiko-Ehmann M, et al. Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 2000; 20: 8745-9.
133. Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem 1997; 272: 6641-6.
134. Vekrellis K, Ye Z, Qiu WQ, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000; 20: 1657-65.
135. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006; 27: 190-8.
136. Sudoh S, Frosch MP, Wolf BA. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and-insoluble pools in CHO-695 cells. Biochemistry 2002; 41: 1091-9.
137. Xie L, Helmerhorst E, Taddei K, et al. Alzheimer's betaamyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002; 22(10): RC221.
138. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162: 313-9.
139. Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H. beta Amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol 2009; 35: 60-8.
140. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162: 313-9.
141. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of beta amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40: 1087-93.
142. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18: 902-4.
143. Martín D, Salinas M, López VR, et al. Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells. J Neurochem 2001; 78: 1000-8.
144. Kounnas MZ, Danks AM, Cheng S, et al. Modulation of gsecretase reduces b-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010; 67: 769-80.
145. Tanzi RE, St. George-Hyslop PH, Haines JL, et al. The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid b protein gene. Nature 1987; 329: 156-7.
146. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-7.
147. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: Systematic meta-analyses herald a new era. Nat Rev Neurosci 2008; 9: 768-78.
148. Lambert J, Heath S, Even G, et al. Genome-wide association study identifies variants at CLUand CR1 associated with Alzheimer's disease. Nat Genet 2009; 41(10): 1094-9.
149. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41(10): 1088-93.
150. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303(18): 1832-40.
151. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7: MS4A6A/MS4A4E, EPHA1: CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43(5): 429-35.
152. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/ MS4A6E, CD2AP, CD33 and EPHA1 are associated with lateonset Alzheimer's disease. Nat Genet 2011; 43: 436-41.
153. Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer's risk in APOE 14 carriers. Neuron 2007; 54: 713-20.